We Do Not Currently List Hello Cake
We do not track current pricing for Hello Cake for erectile dysfunction treatment, so we cannot compare it here. Check pricing and availability with Hello Cake directly.
Browse Erectile Dysfunction Providers
Erectile Dysfunction Providers We Compare
Providers we currently list, with pricing we track
Regulatory noticeRegulatory note (verified October 8, 2026): The FDA reviewed struthealth.com in December 2025 and, on February 20, 2026, issued Strut Health, LLC a warning letter, MARCS-CMS 721448. It raises two separate problems. Pictured product labels carry the "Strut" name, which the agency said represents Strut as the compounder of the semaglutide and tirzepatide products when it is not. The letter also quotes three claims from the site, among them "Generic Zepbound, Mounjaro", along with site copy naming semaglutide and tirzepatide as the active ingredient in the brand medications. Because compounded drugs hold no FDA approval, the FDA said wording of that kind implies one, and it cited misbranding under sections 502(a) and 502(bb) of the FD&C Act. The letter adds that introducing or delivering the products it identifies into interstate commerce is a prohibited act under section 301(a), that receiving them in interstate commerce and delivering or offering to deliver them also violates section 301(c), and that a compounded drug product must meet the conditions of section 503A or 503B of the FD&C Act to be exempt from certain requirements, including the new drug approval requirements. When we checked FDA's warning letter index for Strut Health, LLC on October 8, 2026 it showed no response letter and no close-out letter, so we treat the matter as open. Read the FDA letter
Regulatory noticeRegulatory note (verified October 31, 2026): On September 9, 2025 the FDA sent Hims & Hers Health, Inc. a warning letter covering the Hims brand, MARCS-CMS 716567, drawn from a review of hims.com the previous month. The letter cites two lines of Hims marketing for compounded semaglutide: one presenting it as having the same active ingredient as Ozempic and Wegovy, and one making a clinical-evidence claim for its ingredients. Compounded drug products are not FDA-approved, and the agency’s position is that phrasing of this sort suggests otherwise, which in its view makes the products misbranded under FD&C Act sections 502(a) and 502(bb). A companion letter went to the same company that day for its Hers brand. When we checked FDA’s warning letter index on November 14, 2026 it showed no response letter and no close-out letter, so treat this as open. Read the FDA letter
We review the providers we list on a regular basis, and we may list Hello Cake again in the future.